CHAMPIONS ONCOLOGY ($CSBR) posted quarterly earnings results for Q3 2026 on Thursday, March 12th. The company reported earnings of -$0.02 per share, missing estimates of $0.09 by $0.11. The company also reported revenue of $16,559,999, missing estimates of $16,945,260 by $-385,261.
You can see Quiver Quantitative's $CSBR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CHAMPIONS ONCOLOGY Hedge Fund Activity
We have seen 10 institutional investors add shares of CHAMPIONS ONCOLOGY stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MINK BROOK ASSET MANAGEMENT LLC added 80,305 shares (+inf%) to their portfolio in Q4 2025, for an estimated $554,907
- ACT CAPITAL MANAGEMENT, LLC removed 62,500 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $431,875
- MORGAN STANLEY added 40,059 shares (+21.1%) to their portfolio in Q4 2025, for an estimated $276,807
- HILLSDALE INVESTMENT MANAGEMENT INC. removed 25,100 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $162,522
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 19,811 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $136,894
- ESSEX INVESTMENT MANAGEMENT CO LLC added 18,249 shares (+inf%) to their portfolio in Q4 2025, for an estimated $126,100
- JANE STREET GROUP, LLC removed 17,667 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $114,393
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
